FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1 marker. Trial expands from patients afflicted with Recurrent Grade IV Astrocytoma with IDH1 mutation to those with equally aggressive Recurrent Grade III Astrocytoma with IDH1 mutation. Enrollment in three other NeOnc clinical studies also advance after several published studies indicate the viability of NeOnc's NEO™ plat ...

Proactive has always been a forward looking and enthusiastic technology adopter. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. About this content Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company I ...

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon Powders Subsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT HighTech Materials with Investment Business Operations Jointly Developing Silicon Anode Products with INNOX eco-M's High-Purity Recycled Silicon Development Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - Chief Commercial Officer Melody Harris - Chief Operations Officer and President, Informatics Ali Olivo - EVP, General Counsel and Business Development Conference Call Participants Mark Massaro - BTIG Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Andrew Brackman - William Blair Tejas Savant - Morgan Stanley Mike M ...

For the quarter ended March 2024, NeoGenomics (NEO) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

NeoGenomics (NEO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.01 per share when it actually produced earnings of $0.03, delivering a surprise of 400%.Over the last four ...

Exhibit 99.1 NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Fort Myers, Florida (April 30, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% year-over-year driven by solid execution and teamwork across o ...

Wall Street expects a year-over-year increase in earnings on higher revenues when NeoGenomics (NEO) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. On t ...

Financial Data and Key Metrics Changes - The company reported a revenue increase of 12% year-over-year in Q4 2023, reaching $156 million, driven by growth in clinical test volume and improved revenue per test [10][27] - Adjusted gross profit increased by 17.8% year-over-year, with an adjusted gross margin of 46.7%, reflecting a 225 basis point improvement compared to Q4 2022 [8][34] - Adjusted EBITDA was positive at $9 million, marking a 900% improvement from the prior year [8][11] Business Line Data and Key Metrics Changes - Clinical Services revenue rose by 20% year-over-year to $130 million, supported by a 13% increase in revenue per test and a 6% increase in volume [4][27] - Advanced Diagnostics revenue declined by 17% year-over-year to $26 million in Q4, although it was up 5% sequentially [6][28] - The NGS (Next-Generation Sequencing) segment grew over 40% and now represents over 25% of total clinical revenue [5][28] Market Data and Key Metrics Changes - The company experienced strong growth in the community oncology market, contributing to overall revenue growth [35] - The average revenue per clinical test increased by 13% to $4.41, marking the 11th consecutive quarter of improvement [5][11] Company Strategy and Development Direction - The company aims to become the leading cancer testing information and decision support company, focusing on sustainable long-term growth [1] - Strategic priorities include profitably growing the core business, accelerating advanced diagnostics, and enhancing company culture [36] - The company is investing in digital transformation through a consolidated LIMS system to improve operational efficiency [40][92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue growth target of 10% to 12% for 2024, with adjusted EBITDA expected to grow significantly [55][48] - The company is focused on addressing macroeconomic challenges and optimizing margins through strategic initiatives [6][28] - Management highlighted the importance of customer experience and operational efficiency as key drivers for future growth [141][143] Other Important Information - The company ended Q4 2023 with cash and marketable securities of $415 million, reflecting strong cash flow management [12][53] - The company is actively pursuing litigation related to MRD testing, emphasizing its commitment to serving cancer patients [45][129] Q&A Session All Questions and Answers Question: What is the company's strategy regarding FDA regulations and LDT? - Management indicated that they have been preparing for potential FDA rulings by enhancing their quality systems and ensuring compliance with regulatory standards [63][70] Question: Can you elaborate on the clinical volume growth expectations? - Management noted that they expect clinical volume growth to be driven by a mix of factors including NGS adoption and improved revenue cycle management [67][99] Question: How does the company plan to balance growth and profitability? - Management emphasized the importance of investing in growth initiatives while maintaining a focus on profitability, aiming for a balanced approach [85][106] Question: What are the expectations for the pharma services business? - Management sees significant growth opportunities in pharma services and informatics, with plans to expand the sales force in these areas [108][110] Question: How will the LIMS project impact operational efficiency? - The LIMS project is expected to enhance operational efficiency and productivity, leading to improved margins and turnaround times [92][94]